I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET.
hysterectomy
luteinizing hormone
follicle stimulating hormone
bilateral salpingectomy
dotatate
- 0 views
- 16 Feb, 2024
- 1 location